Global Clinical Portfolio of TB Vaccine Candidates

After decades of complacency in TB vaccine R&D, the late 1990s saw global experts and donors move rapidly to advance the first generation of new TB vaccines into human testing. Today, we focus on developing a diverse and robust portfolio of next generation vaccine candidates. Aeras and others in the TB vaccine field have established global criteria to select, asses and advance promising and novel vaccine candidates in the pipeline.

Around the world, more than a dozen different TB vaccines are in various stages of clinical trials. Aeras is a key partner in several of these development programs, helping advance TB vaccines for the people who need them most.